New Jersey’s only NCI-designated Comprehensive Cancer Center is taking part in a worldwide clinical trial targeting HER2 positive breast cancer, which accounts for up to 25 percent of all breast cancers. Investigators will look at multiple combinations of the drugs Lapatinib and Trastuzumab.
Read the article on Newswise Medical News